ERBB2 and breast neoplasm: For example, plans exist to add the human epidermal growth factor receptor 2 (HER2/neu) marker in the AOL model, and recent developments have given reason to believe that the antigen Ki-67 enhances confidence in prediction of the indication for systemic therapy in breast tumors [33].